LUND, Sweden, July 3, 2024 /PRNewswire/ — Hansa Biopharma, “Hansa” (NASDAQ Stockholm: HNSA), will publish its interim report for January-June 2024 on July 18, 2024. events might be part of the Firm’s quarterly convention name on the identical date at 14:00 CEST/8:00 AM EST. The occasion will probably be hosted by Søren Tulstrup, President and CEO, Matthew Shaulis, CCO and US President, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The decision will embrace a evaluation of the interim outcomes and a enterprise and pipeline replace. It is going to be held in English.
Slides used within the presentation will probably be made obtainable on the corporate web site on the following hyperlink: Monetary reviews.
To take part within the phone convention, please use the dial-in particulars supplied under:
Sweden: +46-8-1241-0952
United Kingdom: +44-203-7696819
United States: +1 646-787-0157
Participant entry code: 765135
The webcast will probably be obtainable on https://hansabiopharma.eventcdn.web/occasions/half-year-january-june-2024
Contacts for extra data:Evan Ballantyne, Chief Monetary [email protected]
Stephanie Kenney, VP World Company [email protected]
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical firm on a mission to develop and commercialize progressive, lifesaving and life-altering remedies for sufferers with uncommon immunological situations. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme remedy, which has been proven to allow kidney transplantation in extremely sensitized sufferers. Hansa Biopharma has a wealthy and increasing analysis and growth program primarily based on the Firm’s proprietary IgG-cleaving enzyme expertise platform, to handle critical unmet medical wants in transplantation, autoimmune ailments, gene remedy and most cancers. Hansa Biopharma is predicated in Lund, Sweden, and has operations in Europe and the U.S. The corporate is listed on Nasdaq Stockholm beneath the ticker HNSA. Discover out extra at www.hansabiopharma.com and comply with us on LinkedIn.
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon emblem, IDEFIRIX, and IDEFIRIX flower emblem are emblems of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
This data was delivered to you by Cision http://information.cision.com
https://information.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-host-q2-2024-interim-results-conference-call,c4006606
The next recordsdata can be found for obtain:
https://mb.cision.com/Principal/1219/4006606/2885437.pdf
240703 – HNSA – Q2 2024 Conf call_ENG invite
